

1. **Full Name:** **Vincenzo Cerullo**
2. **Date and place of birth:** **March 8, 1974, Naples Italy**
Citizenship: Italian
Office address: Cultivator II, Viikinkaari 4, Room A330b, 00790 Helsinki, Finland (Europe)
Home Address: Uimarinpolku 10C 15, 00330 Helsinki, Finland (Europe)
Marital Status: Married, two children (Victor and Nicole)
3. **EDUCATION AND DEGREE AWARDED**
23 Oct 1998 Master of Pharmacy and Pharmaceutical Chemistry (5 years), score 110/110 *cum laude* University of Naples “Federico II”. Title of the Thesis: *Crellastatin A: A Cytotoxic Bis-Steroid Sulfate from the Vanuatu Marine Sponge Crella sp.* Supervisors: Professors Luigi Minale and Mariavaleria D’Auria
3 Jun 1999 Board of Pharmacy
17 Jun 2004 Doctor in Biotechnology, University of L’Aquila and University of Naples “Federico II”. Title of the thesis: *Development of Helper-dependent Adenoviral Vectors for gene therapy of Atherosclerosis.* Supervisors: Professor Lucio Pastore and Professor Fabrizio Pane.
13 May 2011 Docent (equivalent of adjunct professor or senior lecturer) of Experimental Virology, Faculty of Medicine, University of Helsinki.
4. **MOBILITY AND CAREER DEVELOPMENT:**
09/12-to-date **Assistant Professor** (Tenure-Track) and group leader Laboratory of Immunovirotherapy, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki – **Finland Europe**
2011-2012 **Principal Investigator**, Faculty of Medicine, Molecular Cancer Biology Program, University of Helsinki – **Finland Europe**
2009-2011 **Senior Researcher**, Cancer gene Therapy Group, University of Helsinki, **Finland Europe**
2004-2008 **Postdoc**, Department of Human and Molecular Genetics, Baylor College of Medicine, **Houston TX USA**
2001-2004 **PhD student**, CEINGE (Center for Genetic Engineering) and University of Naples “Federico II”, **Italy Europe**
2001 **Exchange PhD student**, Department of Human and Molecular Genetics, Baylor College of Medicine, **Houston TX USA**
1998-2000 **Research Assistant**, Department of Biochemistry and Medical Biotechnology, University of Naples, **Italy Europe**
1993-1998 **Master Student**, Department of Chemistry of the Natural Compounds, University of Naples, **Italy Europe**
5. **LINGUISTIC SKILLS**
Italian: mother tongue **English:** fluent **Spanish:** good **Finnish:** entry (second level Helsingin Aikuisopisto, training still on-going) **Swedish:** good (wife and son Swedish-speaking)
6. **CURRENT POSITION**
Tenure-track assistant professor Faculty of Pharmacy University of Helsinki
Group Leader Laboratory of Immunovirotherapy (IVT_{Lab}) , Division of Pharmaceutical Biosciences and Centre for Drug Research (CDR), Faculty of Pharmacy, University of Helsinki – Finland
7. **PREVIOUS RESEARCH APPOINTMENTS**
1998-2000 Department of Biochemistry and Medical Biotechnology, University of Naples, **Italy Europe** (Research Assistant)
2000-2001 Department of Human and Molecular Genetics, Baylor College of Medicine, Houston TX **USA** (PhD student)
2001-2004 CEINGE (Center for Genetic Engineer) and University of Naples, **Italy Europe** (PhD Student)
2004-2008 Department of Human and Molecular Genetics, Baylor College of Medicine, Houston TX **USA** (Postdoc)
2008-2010 Molecular Cancer Biology Program, Biomedicum University of Helsinki, **Finland Europe** (Senior Researcher)
2011-2012 Molecular Cancer Biology Program, Biomedicum University of Helsinki, **Finland Europe** (University of Helsinki, Adjunct Professor and Principal Investigator)
8. **MAJOR RESEARCH FUNDING AND ACADEMIC LEADERSHIP, STUDENT SUPERVISION**

K. Albin Johanssons stiftelse (PI) (2008-2013) (Lab expenses)	30,000.00€
Sigrid Jusélius Foundation Grant (PI) (2008-2009) (PI's salary)	54,000.00€
FP7-PEOPLE-IRG-2008 (PI) (2009-2013) (Lab expenses)	100,000.00€
University of Helsinki Postdoctoral Researcher (PI) (2010-2013) (PI's salary)	120,000.00€
University of Helsinki Three years research grant (PI) (2013-2015) (Student's salary)	140,000.00€
University of Helsinki Tenure-track (PI) (2012-2017) (PI's salary only)	400,000.00€
Cancer Finnish Foundation (PI) (2014) (Lab expenses)	25,000.00€
Faculty of Pharmacy (PI) (2014) (Lab expenses and infrastructure)	60,000.00€

9. SUPERVISION AND LEADERSHIP

SUPERVISION OF UNDERGRADUATE STUDENTS AND MENTORED MASTER THESIS:

- 2008 Candidate: **Matteo Ugolini**; Score 110/110 *cum laude*; Thesis Title : Manipulating different arms of the immune system to orchestrate tumor-specific immunity and enhance tumor clearance by adenovirus-based gene therapy”
- 2009 Candidate: **Federica Madarena**; Score 106/110; Thesis Title: DC-based cancer immunotherapy
- 2009-2010 Candidate : **Valentina Romano**; Score 110/110 *cum laude*. Thesis Title: CpG-rich oncolytic adenoviruses to enhance tumor clearance stimulating TLR9
- 2011-2012 Candidate: **Mari Hirvinen**; Score *Eximia cum laude approbatur*. Thesis Title: Fcγ receptors polymorphisms as prognostic biomarkers for oncolytic adenovirus therapy.

SUPERVISION OF YOUNG RESEARCHERS AND MENTORED PhD THESIS:

2007-2010 Candidate: **Joao Dias**; Thesis Title: Adenoviral gene therapy for advanced Head and Neck cancer. Approved with distinction by the faculty of Medicine

2010-present Candidate: **Noora Rouvinen**

2011-present Candidate: **Mari Hirvinen**; **Title:** Immunovirotherapy of cancer – Immunological boosting and personalizing of viral cancer therapeutics

2012-present Candidate: **Mariangela Garofalo**; **Title:** Role and use of L-Carnosine in cancer treatment

2012-present Candidate: **Cristian Capasso**; **Title:** Personalized cancer vaccine development

2013-present Candidate: **Lukasz Kuryk**; **Title:** Development of novel immune-boosted oncolytic adenoviruses for treatment of mesothelioma

10. TEACHING DUTIES AND PEDAGOGICAL COMPETENCE/TRAINING

MAJOR TEACHING EXPERIENCE AND DUTIES

- 2003-2004 Series of lectures on Gene Therapy, University of Naples “Federico II“ Faculty of Biotechnology; 5 lectures 120 min each
- 2006 Lecture on use of Helper-dependent Adenoviral vectors, University of Naples “Federico II” Faculty of Medicine; 60 min
- 2008 Lecture on safety and toxicity of adenoviral vector, University of Helsinki Faculty of Medicine, Haartman Institute; 45 min
- 2010 Series of lectures on the use of adenovirus as vector for cancer gene therapy and gene replacement, Department of Immunology University of Verona; 3 lectures 60 min each
- 2011 Public Lecture on use of Adenovirus-derived vectors for gene therapy, University of Helsinki
- 2012 Lecture on Pharmacokinetic of viral vectors for Gene Therapy; course of Advances Biopharmaceutics
- 2013 Gene and Cell therapy lectures for the course - Biopharmaceutics II
- 2013-2014 Advanced Course in Immunology (A course that I have completely developed for the Faculty of Pharmacy, 6 credits with theory and practice)

PEDAGOGICAL and LEADERSHIP COMPETENCE AND TRAINING

- 2010 University of Helsinki Pedagogy I training course, “Teaching and Learning in higher education” (YP1) and “design and implementation and assessment of teaching” (YP2) (10 credits). Score: *excellent*
- 2011 University of Helsinki Pedagogy II training course, “Academic Supervising” (5 credits). Score: *Very Good*
- 2014 University of Helsinki Leadership course training course, “Academic Leadership” (5 credits).

11. SCIENTIFIC AWARDS AND HONORS:

- 1993 Scholarship at Pharmaceutical Chemistry Department of University of Naples
- 1998 “SOCRATES” Scholarship at “Universitat de Barcelona” Spain
- 1998 University of Naples, special mention and publication of the thesis
- 1999 Award from Società Chimica Italiana (Italian Society of Chemist) for the Master thesis
- 2005 Award for presentation at *Cell and Gene Therapy*, Galveston TX USA
- 2012 “New investigator of the month” awarded by the American Society of Gene Therapy

- 2013 Nomination for **Outstanding New investigator at ASGCT** (American Society of Gene and Cell Therapy).
- 2014 Nomination for **Outstanding Young investigator at ESGCT** (European Society of Gene and Cell Therapy); decision to be made in late September.

12. OTHER SCIENTIFIC OR ACADEMIC MERITS AND ACTIVITIES

INVITED oral presentation at international conferences (selected from 16)

1. **V. Cerullo, W. McCormack, V. Mane, M.P. Seiler, R. Garcia, C. Clarke, S. Pipe, B. Lee. Long-term phenotypic correction of murine Hemophilia A and immunological differences of bioengineered FVIII variants delivered by helper-dependent adenoviral vectors.** 10th Annual Meeting of the American Society of Gene Therapy -2007, Seattle WA
2. **V. Cerullo, M Seiler, D. Wang, V Mane, C Clarke, B Lee. Toll-like receptors activation in the innate and adaptive immune response to Helper Dependent Adenoviral Vectors.** 10th Annual Meeting of the American Society of Gene Therapy -2007, Seattle WA
3. **Vincenzo Cerullo, Michael P. Seiler, Peleg Ben-Galim, Christian Clarke, Aylet Erez, Michael A. Barry, Brendan Lee. Retargeting Metabolically Biotinylated Helper Dependent Adenovirus to Cartilage in the Knee Joint and Intervertebral Disc.** 11th Annual Meeting of the American Society of Gene Therapy – 2008, Boston MA
4. **Vincenzo Cerullo, Nicola Brunetti-Pierrri, Racel Cela, Donna J. Palmer, Phil Ng, Brendan Lee. Long-Term Phenotypic Correction of Murine von Willebrand Disease by Helper Dependent Adenovirus Gene Transfer.** 11th Annual Meeting of the American Society of Gene Therapy – 2008, Boston MA
5. **Cerullo Vincenzo, Diaconu Iulia, Ugolini Matteo, Nokisalmi Petri, Pesonen Sari, Haavisto Elina, Hemminki Akseli. Oncolytic adenovirus expressing Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) for treatment of cancer.** 9th International adenovirus meeting – 2009, Dobogoko Hungary
6. **Cerullo Vincenzo, Noora Rouvinen, Iulia Diaconu, Lotta Kangasmiemi, Maria Rajecki, Sari Pesonen, Petteri Arstila, Hemminki Akseli. Immunological effect of three different schedules of low dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.** 6th International Conference on Oncolytic Viruses as Cancer Therapeutics – 2011, Las Vegas, NV USA
7. **Vincenzo Cerullo, Valentina Romano, Iulia Diaconu, Matteo Ugolini, Noora Rouvinen-Lagerström, Akseli Hemminki. Arming adenovirus with CpG motifs to stimulate innate and adaptive immune response to enhance anti-tumor efficacy.** 14th Annual Meeting of the American Society of Gene and Cell Therapy -2011, Seattle WA
8. **Vincenzo Cerullo, Iulia Diaconu, Sirkka-Liisa Holm, Dario Greco, Akseli Hemminki. Novel CpG-rich oncolytic adenovirus backbone to stimulate tumor-specific immune response and block the suppression of Myeloid-derived Suppressive Cells.** 15th Annual Meeting of the American Society of Gene and Cell Therapy - 2012, Philadelphia PA
9. **Cristian Capasso, Mari Hirvinen, Kilian Guse, Marko Ahonen, Dario Greco, Markus Vähä-Koskela, Akseli Hemminki, Vincenzo Cerullo. DAI-armed double deleted oncolytic vaccinia virus displays enhanced anti-tumor activity.** European Society of Gene and Cell Therapy 2013 Madrid, Spain.
10. **Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitry Romanyuk, Lukasz Kuryk, Maxim Antopolsky, Arto Urtti, Vincenzo Cerullo. Oncolytic adenovirus loaded with MHC-I restricted peptide as platform for oncolytic vaccine.** American Society of Gene and Cell Therapy 2014, Washington DC, USA.

INVITED seminars to foreign Universities as expert in Gene Therapy (Selected from 12)

- 2012 Adenovirus-gene therapy from bench to bedside, CEINGE and University of Naples (IT)
- 2012 Oncolytic viruses for Cancer gene therapy, University of Liverpool (UK)
- 2013 Adenovirus-gene therapy from bench to bedside, Telethon Institute of Genetics and Medicine (TIGEM), Naples (IT)
- 2014 Oncolytic Vaccines for cancer treatment, Faculty of Pharmacy University of Naples “FedericoII”
- 2014 Oncolytic Vaccines for cancer treatment, Faculty of Pharmacy University of Naples “FedericoII”
- 2014 Oncolytic Vaccines for cancer treatment, Istituto per la cura di tumor G. Pascale

13. PATENTS AND INVENTIONS

1. Title: “Antigen specific immunosuppression by dendritic cell therapy”
Patent No. : US20080311140
2. Title: “Adenoviral vectors and methods and uses related thereto”
Patent No. : Finnish patent office 20095466
3. Title: “Non-Ad5 adenoviral vectors and methods and uses related thereto”

Patent No. : Finnish patent office 20095751

4. Title: Ad5D24-CD40L-family, Finnish Patent pending, **application #20105988**
5. Title: Ad5D24-CTLA4-family, Finnish Patent pending, **application #20105991**
6. Title: VVDD-CD40L-family, Finnish patent pending, **application #20115914**
7. Title: VVDD-CD40L-family, US patent pending, **application #61/535429**
8. "Novel therapeutic vectors", Finnish **application #20116181** and US application #61/563,634
9. "Novel therapeutic vectors", US **application #61/563,634**
10. "Personalised peptide-coated viruses – **PeptiCrad**, FI patent application No. 20145449 filed on 19.5.2014, entitled "Modified adenoviruses for cancer vaccines development"

14. SCIENTIFIC SOCIETIES

American Society of Gene and Cell Therapy, European Society of Gene and Cell Therapy, Finnish Society of Gene Therapy

15. POSITION OF TRUST

- **Editorial Board of:** *Molecular Therapy Oncolytics, Biomedicines*
- **Guest Editor of Biomedicines for the special issue** "Gene therapy for cancer treatment"
- **Official Grant Reviewers** for: American Institute for cancer Research (**AICR**), The welcome Trust UK, Swiss National Science Foundation
- **Board of Immune Response to Gene and Cell Therapy Committee of ASGCT** (2013 - 2016)
- **American Society of Gene and Cell Therapy (ASGCT):** abstract review committee and co-Chair of: the Adenovirus and double stranded virus section (Philadelphia, 2012); Immunotherapy section (Salt-lake city 2013)
- **Ad hoc reviewer for:** *Molecular Therapy, Human Gene Therapy, Gene Therapy, Cancer Research, Clinical Cancer Research, International Journal of Cancer, Journal of Gene Medicine, PlosOne, among others*
- **Evaluator for the Italian professorship** evaluation; selected from 1700 applicants by ANVUR (2013)

16. NATIONAL AND INTERNATIONAL COLLABORATIONS (Short List)

International: Dotti Giampietro (Texas Children Hospital), Masataka Suzuki (Center for Gene and Cell Therapy (CGCT) Houston TX), Brendan Lee (Baylor College of Medicine, Houston TX), Markus Moehler (Mainz, Germany), Gennaro Piccialli (Naples, Italy), Davide Melisi (Verona, Italy)

National: Brendan Buttersby, Akseli Hemminki, Markku Variosalu, Arto Urtti (University of Helsinki), Ari Hinkkanen, Jarko Ketolainen (University of Eastern Finland).

17. OVERALL SCIENTIFIC IMPACT OF THE CANDIDATE'S RESEARCH:

Summary Table	
Total peer-reviewed articles (already accepted and indexed)	60
Total articles in submission not yet accepted at the time of deadline	7
First Authorship	9
Second Authorship	6
Last and/or corresponding authorship	17
<i>h index</i>	19
Total citations	1082
Patents and Invention	10
Book Chapters	5
Invited Oral presentation at International Meetings	16

*Have been recently submitted and not printed yet